CClinicalTrials.gg
CompletedNCT04043169Updated Feb 20, 2020

Clearblue Pregnancy Test - Lay User Study

An observational study in Pregnancy, sponsored by SPD Development Company Limited. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2020-02-20.

Sponsored by SPD Development Company Limited · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
204
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The Clearblue home pregnancy test (HPT) is an over-the-counter urine hCG (human chorionic gonadotropin) integrated digital test which is intended for the detection of pregnancy. This study will assess the performance of a HPT in the hands of lay-users by comparing their results when used according to the instructions for use (IFU) to (i) confirmed pregnancy status of the volunteers and (ii) to the results of trained study staff testing the same urine samples.

Read the detailed description

The Clearblue product is an over-the-counter urine hCG (human chorionic gonadotropin) integrated digital test which is intended for the detection of pregnancy. The test is indicated for use from 6 days before the day of the missed period (5 days before the day of the expected period). The test is intended for home use.

This study aims to demonstrate that the Pregnancy Test has the required performance characteristics in lay-user testing, and when testing samples provided by lay-users. The study will recruit a cross-section of the target pregnancy test user population, that is, women aged between 18 and 45 representative of the intended user.

A minimum of 204 volunteers will be required to complete the study. The study site will aim to recruit an equal number of pregnant and not-pregnant volunteers (a minimum of 102 of each). Each volunteer will conduct the pregnancy test using both the 'in stream' and 'dip' method of sampling. Volunteer results will be evaluated against confirmed pregnancy status.

02

Conditions studied

  • Pregnancy
03

In context

Lead sponsor

SPD Development Company Limited is the lead sponsor of 30 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Healthy pregnant, or not pregnant volunteers requiring or wishing to conduct a pregnancy test.

Inclusion criteria

  • Female
  • Aged 18 to 45
  • Willing to conduct a pregnancy test to determine or confirm their pregnancy status
  • Willing to reveal their pregnancy status
  • Willing to provide a blood sample
  • Willing to give informed consent

Exclusion criteria

Exclusion Criteria:

  • Significant affiliation with SPD
  • Has professional experience of using lateral flow-based devices
  • Beyond the first trimester of pregnancy
  • Taken a hormonal preparation containing hCG in the last month.
  • Has a medical condition that means that it is not appropriate to give a blood.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
204 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • Diagnostic testClearblue pregnancy test

    Urine pregnancy test

06

What researchers measure

Primary outcomes

  1. Accuracy of Clearblue pregnancy test

    Number of pregnancy test results in agreement with clinical pregnancy status

    Time frame: 3 days

Secondary outcomes

  1. Sample method agreement

    number of volunteers who record the same pregnancy test result using the 'in stream' and 'dip' method of sampling

    Time frame: 1 day

  2. Coordinator agreement

    number of volunteers who record the same pregnancy test result as a trained study coordinator

    Time frame: 1 day

  3. Device usability

    number of volunteers who record the device as easy to use

    Time frame: 1 day

07

Study locations

1 site
  • WCCT
    Cypress, California 90630, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04043169
Lead sponsor
SPD Development Company Limited
Collaborators
WCCT Global
Responsible party
Sponsor
First posted
Aug 2, 2019
Start date
Jul 30, 2019
Primary completion
Nov 30, 2019
Completion
Dec 31, 2019
Last update
Feb 20, 2020

Study contacts

Sarah Johnson
study director · SPD Development company Ltd.

Oversight

Data monitoring committee
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion